Incyte | INCY - Trade Creditors


Incyte reported $228.62M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 12.25M 1.34M Mar/2026
Agenus USD 71.08M 11.9M Mar/2026
Agios Pharmaceuticals USD 13.75M 4.61M Mar/2026
Alnylam Pharmaceuticals USD 126.63M 10.91M Mar/2026
Amgen USD 19.52B 1.37B Mar/2026
BioCryst Pharmaceuticals USD 10.96M 4.87M Mar/2026
Biogen USD 358.5M 73.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 4.23B 659M Mar/2026
Eli Lilly USD 5.03B 350M Mar/2026
Exelixis USD 24.15M 5.47M Mar/2026
Gilead Sciences USD 645M 70M Mar/2026
Incyte USD 228.62M 1.41B Mar/2026
Ionis Pharmaceuticals USD 26.03M 2.05M Mar/2026
MacroGenics USD 4.29M 500K Mar/2026
Merck USD 3.86B 541M Mar/2026
Moderna USD 161M 156M Mar/2026
Nektar Therapeutics USD 10.77M 4.79M Dec/2025
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novartis USD 4.32B 134M Mar/2026
Novartis USD 4.32B 134M Mar/2026
Pfizer USD 4.51B 734M Mar/2026
PTC Therapeutics USD 25.48M 20M Mar/2026
Puma Biotechnology USD 6.39M 962K Sep/2025
Regeneron Pharmaceuticals USD 1.03B 4.81B Mar/2026
Sarepta Therapeutics USD 70.38M 210.46M Mar/2026
Ultragenyx Pharmaceutical USD 42M 11M Mar/2026
Vertex Pharmaceuticals USD 3.47B 40.6M Mar/2026